Background. Hyperphosphataemia in patients on haemodialysis (HD) can lead to, or worsen, secondary hyperparathyroidism (with associated bone disease) and extra-skeletal calcifications associated with increased cardiovascular morbidity and mortality. MCI-196 is a new, non-absorbed, non-calcium-based phosphate binder. The aim of this study was to determine the effect of three fixed doses of MCI-196, on serum phosphorus level and other parameters relevant to HD patients. Methods. A total of 120 chronic kidney disease (CKD) stage 5 patients on HD and with the serum phosphorus level >2.1 mmol/l were randomized to receive double-blind treatment with either 3, 6 and 9 g/day MCI-196 or placebo for 3 weeks. Results. Serum phosphorous decreased in all three treatment groups (−0.038, −0.268 and −0.257 mmol/l in the 3, 6 and 9 g/day groups, respectively). The difference between treatment and placebo groups was significant for the 6 and 9 g/day groups (P < 0.05 in both cases). Changes in the mean serum calcium were minimal and without relevant differences between groups. However, calciumphosphorus product (Ca × P) was significantly reduced in the 6 and 9 g/day groups P < 0.05). MCI-196 at all doses decreased serum intact PTH between baseline and endpoint, and differences between treatment groups and placebo were statistically significant for the 3 and 9 g/day groups (P < 0.02 in both cases). Both serum total and LDL cholesterol decreased significantly in all treatment groups compared to placebo (by 0.71-1.05 mmol/l, for total cholesterol and 0.68-0.94 mmol/l for LDL cholesterol P < 0.001 in all cases). There was minimal change in serum HDL cholesterol. MCI-196 at all doses decreased significantly serum uric acid between baseline and endpoint compared to placebo (P < 0.005 in all cases). The drug was well tolerated.
Introduction
Hyperphosphataemia is known to be associated with high mortality rates in dialysis patients, can lead to, or aggravate, secondary hyperparathyroidism and is also known to be an important factor in soft tissue calcification [1] [2] [3] . Although the risks are generally recognized, a significant proportion of dialysis patients still have hyperphosphataemia [4] . Evidence-based guidelines developed for the management of abnormal mineral metabolism (K/DOQI) [5] recommend that phosphorus levels are maintained within a target range of 1.13-1.78 mmol/l and that the calciumphosphorus product (Ca × P) should be <4.4 mmol 2 /l 2 . However, it has been indicated that current practice for the management of bone and mineral metabolism in haemodialysis (HD) falls short of meeting these guidelines [6] [7] [8] [9] , thus highlighting the need for more effective treatments.
Calcium-based phosphate binders can lead to raised serum calcium concentration and an increased level of Ca × P, resulting in an increased risk of parenchymal and vascular calcifications. This risk is further increased in patients taking vitamin D and also with its analogues and high calcium dialysate [3, 10] . Vascular calcification in HD Effect of MCI-196 on serum phosphate and cholesterol levels in HD patients with hyperphosphataemia 575 patients may represent an independent prognostic marker for all cause and cardiovascular mortality [11] . On the other hand, the long-term use of aluminium-containing binders, although effective, has largely been reduced due to welldocumented side effects including bone disease, anaemia and encephalopathy [12] [13] [14] . It is now recommended that these compounds should be reserved for patients with serum phosphorus >2.26 mmol/l and only for short-term therapy [5, 15] .
An ideal phosphate binder should be well tolerated, nonaccumulating, non-toxic, bind phosphate effectively and not result in hypercalcaemia. Studies with sevelamer hydrochloride have shown the possibility of developing the use of an anion exchange resin as a phosphate binder. Compared with calcium-based phosphate binders, sevelamer is less likely to cause hypercalcaemia, low levels of intact PTH, and progressive coronary and aortic calcification in HD patients [16] . Sevelamer also has additional effects on serum lipids, by lowering total and LDL cholesterol [17] .
A new, non-metallic, anion exchange resin MCI-196 (chemical name: 2-methylimidazole polymer with 1 chloro-2,3-epoxypropane) has been approved for use in Japan for the treatment of hypercholesterolaemia at a dose of 3 g/day. In in vitro studies, MCI-196 has also shown stable phosphorus-adsorption activity over a wide range of pH. Pre-clinical studies show that MCI-196 is able to improve hyperphosphataemia in rats with renal failure induced by adenine administration for 4 weeks. Therefore, orally administered MCI-196 may be expected to adsorb phosphate in the intestine, to enhance faecal excretion of phosphorus and to improve hyperphosphataemia in chronic kidney disease (CKD) patients on dialysis.
The aim of this study was to evaluate the effect of fixed doses of MCI-196 on serum levels of phosphorus and its safety and tolerability in patients with CKD stage 5 HD patients with hyperphosphataemia.
Subjects and methods

Patients
Eligible patients had a diagnosis of CKD stage 5, had been both clinically stable on three times weekly HD and had stable phosphate control using a calcium-based phosphate binder or sevelamer as monotherapy for at least 3 months. Inclusion criteria required a serum phosphorus level <2.1 mmol/l at screening, calcium dialysate content between 1 and 1.75 mmol/l, be on a stabilized phosphorus diet and baseline fractional clearance of urea (Kt/V) (single pool) of at least 1.05. Exclusion criteria included diabetes with severe peripheral vascular disease, cardiovascular disease, gastrointestinal motility problems, liver dysfunction and severe hypertension. Patients already treated with vitamin D preparations could maintain this therapy during the study, provided the dose during the treatment phase remained stable, unless a significant increase in parathyroid hormone (PTH) level was observed. Oral calcium supplements were forbidden; however, rescue therapy was permitted in the case of hypocalcaemia (serum corrected calcium <2.12 mmol/l) or significant reduction (i.e. >0.25 mmol/l) in baseline serum calcium levels. In this case, oral elemental calcium supplementation 1.5 g/day or 2 g/day (depending on calcium diet content) could be taken just before sleeping or 2-4 h the last meal.
Study design
This was a double-blind, randomized, placebo-controlled, fixed-dose study consisting of a basic 2-week washout period of phosphate binder therapy followed by a 3-week treatment period with the tested drug, involving a total of six clinic visits. Patients at the end of the washout period whose serum phosphorus level (measured at a site laboratory) had increased by at least 15% and reached a serum phosphorus level >2.1 mmol/l were eligible for the subsequent stage of the study. If, during the washout period, the serum phosphorus level reached 2.9 mmol/l or greater, the patient could proceed immediately to baseline assessments and be randomized. The washout period could be extended by up to 1 week if the serum phosphorus level had not reached a qualifying level (≥2.1 mmol/l and 15% increase from screening) before the target day for randomization.
Eligible patients were randomized to receive double-blind treatment with 3 g/day MCI-196, 6 g/day MCI-196, 9 g/day MCI-196 or placebo for 3 weeks. MCI-196 was administered as tablets containing 500 mg of active medication. Placebo tablets were of similar appearance. The dose was 6 tablets taken three times a day after meals. During the treatment phase, the patients were seen weekly for 3 weeks. The patients were required to remain on three sessions of HD weekly during the study, with a stable session length lasting for 3-5 h. The patients were advised to maintain a stable phosphorous diet throughout the length of the study. Safety was evaluated by spontaneous adverse event (AE) reporting and vital signs (body temperature, weight before and after dialysis, systolic blood pressure, diastolic blood pressure and pulse rate) at each visit. Samples for haematology, biochemistry, coagulation and HbA 1c were taken at all visits and sent to a central laboratory for assay.
The primary efficacy parameter was reduction in serum phosphorus as measured by the reduction from baseline to endpoint in serum phosphorus levels, as determined by a central laboratory using a colorimetric method (ammonium molybdate). The phosphorus level was monitored weekly during the treatment period. The secondary efficacy parameters were serum calcium and Ca × P levels, intact parathyroid hormone (iPTH), total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides and uric acid.
The study was conducted in accordance with good clinical practice (GCP) as required by International Conference on Harmonisation (ICH) guidelines, and standard operating procedures (SOPs) for clinical investigation and documentation. The clinical study protocol, informed consent form(s), protocol amendments and all other appropriate study-related documents were reviewed and approved by local IECs constituted in accordance with national regulations as applicable. Informed consent was obtained before a patient was enrolled in the study and prior to the commencement of any protocol-driven activities. The investigator or designee met with the patient and explained the study in sufficient detail to permit an informed decision to participate.
Statistical analyses
The intent-to-treat (ITT) population, which consisted of all patients who were randomized, took study medication and had at least one subsequent efficacy evaluation, was considered the primary analysis population. The safety population consisted of all randomized patients who took study medication and had at least one post-randomization efficacy evaluation. For the primary and secondary parameters, a last observation visit was created by carrying forward the last post-baseline observation (last observation carried forward) for those patients who withdrew prior to visit 6 (week 3). All data were summarized by treatment groups, and where appropriate, a total column was included to summarize all patients.
The primary variable of change in serum phosphorus from baseline (visit 3) to endpoint was analysed using analysis of variance (ANOVA) with treatment and centre (pooled) as independent variables. The value of including baseline serum phosphorus as a covariate was also investigated. Each dose of MCI-196 was compared to placebo. Least square means and confidence intervals were calculated and presented for the difference of each dose group to placebo. The Cochran Mantel-Haenszel test controlling for centre (pooled) was used to analyse the comparisons of each dose of MCI-196 to placebo at the last observation visit.
The change in each secondary efficacy parameter from baseline to endpoint was analysed using ANOVA with treatment and pooled centre as independent variables. The effect of including baseline levels as a covariate was also investigated. Each dose of MCI-196 was compared to placebo within the framework of the ANOVA using suitable contrasts. Least square means and confidence intervals were calculated and presented for the difference of each dose group to placebo.
The study was not powered to detect any difference between the three doses of MCI-196; however, this comparison was presented for primary and secondary variables as an exploratory comparison for information. 
Results
Study subjects
In total, 202 Caucasian patients were screened and 120 patients were randomized at 19 centres. The study took place between April and July 2003. Failure of screened patients to be randomized was due to the inability to meet all inclusion/exclusion criteria at the moment of randomization-often inability to demonstrate a 15% increase in serum phosphorus level after washout and simultaneously be >2.1 mmol/l. A total of 29 patients were randomized to MCI-196 3 g/day, 30 to MCI-196 6 g/day, 32 to MCI-196 9 g/day and 29 to placebo. A single patient in the MCI-196 9 g/day group was excluded from all analysis populations, including the safety population, as this patient did not take any study medication. A total of 111 patients completed and 9 patients discontinued treatment during the study. In the analysis populations, overall, there were 74 male and 45 female patients, mean age 51.4 ± 11.8 years (mean ± SD). A summary of treatment groups and disposition by treatment, including reasons for withdrawal is shown in Table 1 .
All patients in the control group took at least 80% of their study medication. Overall compliance (assessed by dispensing and return records and from unused return drug samples) was similar in the three active treatment groups with 86.2% of patients in the 3 g/day, 93.3% in the 6 g/day and 90.3% in the 9 g/day group taking at least 80% of the study medication. At baseline, the treatment groups were generally comparable for all characteristics ( Table 2) . The Kt/v and predialysis blood urea nitrogen (BUN) values were similar across all groups both at baseline and at end of the study and stable throughout the study (data not shown). Kt/v values were as follows: 1.22, 1.19, 1.28, 1.25 for 3, 6, 9 g/day and placebo, respectively, at baseline and 1.28, 1.24, 1.31 and 1.28 at end of the study.
Efficacy results
Mean serum phosphorus rose in all groups between screening, washout and baseline, due to cessation of previous phosphorus-reducing medication. At baseline, the mean serum phosphorus was slightly higher in the 6 g/day and 9 g/day MCI-196 groups compared to placebo (2.308 mmol/l, 2.330 mmol/l versus 2.292 mmol/l, respectively) and slightly lower in the 3 g/day group (2.153 mmol/l). During treatment, the mean serum phosphorus tended to decrease over time in the active treatment groups, with a greater decrease in the 6 g/day and 9 g/day groups compared to the 3 g/day and placebo groups ( Table 3 ). The mean change in serum phosphorus from baseline to endpoint was −0.038 mmol/l in the 3 g/day group, −0.268 mmol/l in the 6 g/day group, −0.257 mmol/l in the 9 g/day group and −0.039 mmol/l in the placebo group (Figure 1) . The mean change was statistically significantly greater in the 6 g/day and 9 g/day groups compared to placebo (P = 0.027, P = 0.043, respectively). There was no significant difference between active treatments. In all active treatment groups, patients with baseline serum phosphorus ≥2.4 mmol/l showed a greater reduction than patients with baseline values <2.4 mmol/l (Table 4) .
Secondary efficacy parameters
There were no relevant differences in the mean serum calcium between groups at baseline or endpoint, and changes in the mean serum calcium were minimal and nonsignificant. The mean serum calcium values at baseline were 2.25, 2.36, 2.28 and 2.34 mmol/l for 3, 6, 9 g/day MCI-196 and placebo, respectively. The mean serum calcium levels at end of study were 2.23, 2.33, 2.28 and 2.34 mmol/l for 3, 6, 9 g/day MCI-196 and placebo, respectively.
The mean decrease in Ca × P was statistically significantly greater in the MCI-196 6 g/day group compared to placebo (−0.717 mmol 2 /l 2 versus −0.109 mmol 2 /l 2 , P = 0.020) and in the MCI-196 9 g/day group compared to placebo (−0.625 mmol 2 /l 2 versus −0.109 mmol 2 /l 2 , P = 0.022) (Figure 2 ). All active treatment groups showed a mean decrease in serum iPTH between baseline and endpoint (3 g/day −6.438 pmol/l, 6 g/day −4.440 pmol/l, 9 g/day −4.447 pmol/l), while the placebo group showed an increase (2.200 pmol/l). There was a statistically significant difference between 3 g/day and 9 g/day MCI-196 and placebo (P = 0.014, P = 0.007, respectively). The mean PTH values at baseline were 37.20, 37.61, 22.80 and 34.98 pmol/l for 3, 6, 9 g/day MCI-196 and placebo, respectively. The mean levels at the end of the study were 30.76, 33.17, 18.35 and 37.18 for 3, 6, 9 g/day MCI-196 and placebo, respectively.
All active treatment groups showed a mean decrease in serum uric acid between baseline and endpoint (3 g/day −0.027 mmol/l, 6 g/day −0.029 mmol/l, 9 g/day −0.020 mmol/l), while the placebo group showed a mean increase (0.019 mmol/l). There was a statistically significant difference between MCI-196 3 g/day, 6 g/day and 9 g/day and placebo (P = 0.004, P = 0.001, P = 0.003, respectively).
Lipid parameters
All MCI-196 groups showed a mean decrease (up to 22.5%) in serum total cholesterol between baseline and endpoint (3 g/day −0.716 mmol/l, 6 g/day −0.849 mmol/l, 9 g/day −1.051 mmol/l), while the placebo group showed a small mean increase (0.090 mmol/l) ( Figure 3 ). There was a statistically significant difference between MCI-196 3 g/day, 6 g/day and 9 g/day and placebo (P = 0.001, in all cases). There were minimal changes in the mean serum HDL cholesterol over the course of the study, but no relevant treatment-related differences. All active treatment groups showed a mean decrease in serum LDL cholesterol between baseline and endpoint up to 39.6% (3 g/day −0.680 mmol/l, 6 g/day −0.786 mmol/l, 9 g/day −0.943 mmol/l), while the placebo group showed a small mean increase (0.010 mmol/l) (Figure 4 ). There was a statistically significant difference between MCI-196 3 g/day, 6 g/day, 9 g/day and placebo (P = 0.001, in all cases) (Figure 4) . The 3 g/day and 6 g/day groups showed a mean decrease in serum triglyceride level between baseline and endpoint (−0.232 mmol/l, −0.344 mmol/l, respectively), while the 9 g/day and placebo groups showed a small mean increase (0.047 mmol/l, 0.067 mmol/l, respectively). There was a statistically significant difference between MCI-196 6 g/day and placebo (P = 0.017).
Safety
Treatment-emergent AEs were experienced by 10 (34.5%) patients receiving MCI-196 3 g/day, 12 (40.0%) patients Results are shown as mean ± SEM. * Significant difference from baseline (P < 0.05), * * significant difference from baseline (P < 0.01). receiving MCI-196 6 g/day, 12 (38.7%) patients receiving MCI-196 9 g/day and by 4 (13.8%) patients receiving placebo. The most commonly recorded events were GI disorders; a total of 54 AEs in 25 patients. In total, five patients withdrew from the study due to treatment emergent AEs, 1 (3.4%) in the 3 g/day, 2 (6.7%) in the 6 g/day and 2 (6.5%) in the 9/day MCI-196 groups. Treatment-emergent AEs reported by 5% or more of patients in any group are shown in Table 5 .
GI AEs were experienced by 5 (17.2%) patients receiving MCI-196 3 g/day, 10 (33.3%) patients receiving MCI-196 6 g/day, 8 (25.8%) patients receiving MCI-196 9 g/day and by 2 (6.9%) patients receiving placebo. Nausea was experienced by two patients in the 3 g/day group and five each in the 6 g/day and 9 g/day groups. Vomiting was experienced by three patients in the 6 g/day group and four patients in the 9 g/day group. Most AEs were considered by the investigators to be mild or moderate in severity. Table 5 . Treatment−emergent AEs experienced by ≥5% patients in any treatment group, by body system and preferred term-safety population MCI-196 MCI-196 3 g/day 6 g/day 9 g/day Placebo Total Serious AEs (SAEs) were rare, and there was no obvious relationship with study treatment. There were no studyemergent SAEs in randomized patients.
MCI-196 did not appear to have any clinically relevant effects on laboratory values, physical examination findings, ECGs or vital signs.
Discussion
In the present study, MCI-196 at doses of 6 g/day and 9 g/day reduced the mean serum phosphorus levels over a 3-week treatment period, and reductions were significantly larger than those observed in placebo-treated patients at endpoint. Patients with higher serum phosphorus at baseline showed a greater reduction in serum phosphorus than patients with lower baseline values. MCI-196 treatment significantly reduced Ca × P, serum levels of iPTH and uric acid, but did not have an adverse effect on serum calcium levels. In addition, MCI-196 significantly reduced serum levels of total cholesterol, LDL cholesterol and triglycerides, but did not affect serum HDL cholesterol levels.
Patients were advised to maintain a stable phosphorous diet and Kt/V, and predialysis BUN levels were stable throughout the study suggesting a constant dietary protein and phosphorus intake. Moreover, the random allocation of patients in four double-blind study groups reduced any possibility of bias due to diet.
Our results are similar to those reported previously by Kurihara et al. for a double-blind placebo controlled study of 6 g/day MCI-196 administered for a period of 2 weeks [18] . In this study, the serum phosphate in the placebo group increased by 0.27 mmol/l, while serum phosphate in the MCI-196 group decreased by 0.17 mmol/l. In our current study, after 2 weeks of treatment with 6 g/day MCI-196, serum phosphorus in the placebo group increased by 0.02 mmol/l while serum phosphorus in the treated group decreased by 0.20 mmol/l. A comparison of the reduction in serum LDL cholesterol and total cholesterol levels in the two studies was −34.2% (LDL) and −21.3% (total) in the Kurihara study and 33.7% and 20.47%, respectively under comparable conditions in our study. Thus, these two studies show a remarkable similarity in response to 6 g/day MCI-196 in terms of lowering phosphorus and LDL cholesterol, despite these being two very different populations with diverse dietary habits.
Current therapy for hyperphosphataemia comprises treatment with calcium-based binders, sevelamer and more recently lanthanum carbonate. The use of aluminium-based compounds has been substantially reduced due to its potential toxicity. Although calcium-based treatment is cost effective, hypercalcaemia in HD patients is a common consequence of the use of calcium-based phosphate binders, especially in combination with vitamin D treatment [19] . There are concerns about the effect of an increased calcium load, particularly on parenchymal and vascular calcification, that may contribute to the development of cardiovascular disease and have an impact on all-cause and cardiovascular mortality [11] . In our study with MCI-196, the changes in the mean serum calcium in the treatment groups were minimal. Elevated levels of Ca × P in HD patients also play a pivotal role in vascular calcification, cardiovascular disease, calciphylaxis and death [20, 21] , although recently the major role of the single values (Ca and P) has been better clarified. In both MCI-196 6 g/day and 9 g/day groups, the mean decrease in Ca × P was significantly greater compared to placebo.
The recent DCOR study has shown that overall, sevelamer-treated HD patients had a non-significant, 9% reduction in the risk of death (primary endpoint) from any cause compared to calcium-based binders [22] except for patients aged over 65 years (secondary endpoint) that were 34% less likely to die from all causes than those using calcium-based phosphate binders for the same period [22] .
In addition, there was evidence that sevelamer use resulted in a 10% decrease in the all-cause hospitalization rate and a 12% decrease in the number of all-cause hospital days compared with calcium-based phosphate-binder [23] . The mean reduction in serum phosphorus from baseline seen in our study in the MCI-196 6 g/day group (2.308-2.04 mmol/l) is comparable to that shown in the sevelamer CARE study [24] . Despite an escalating dosage (up to 9 g/day sevelamer) and a higher mean baseline serum phosphorus in the CARE study, the potency of MCI-196 and sevelamer would appear to be similar when comparing results in the two studies after a 3-week period (average sevelamer dose at this time 4.6 g/day), in patients with a baseline serum phosphorus >2.4 mmol/l. In both studies, the mean serum phosphorus after treatment for 3 weeks did not reach the guideline target level of 1.78 mmol/l. Whether a greater reduction occurs after a longer period of treatment with MCI-196 remains to be evaluated. The time course of the reduction in serum phosphorus levels in this study shows no evidence of having plateaued or reached a maximum level of serum phosphorus reduction after 3 weeks therapy. In addition, there is no evidence that the maximum effective dose has been reached. Thus, at present, the results of the present study do not claim to demonstrate the maximum efficacy of MCI-196 in reduction of serum phosphorus. In addition, it is envisaged that MCI-196 could be used as a longer-term therapy or possibly in combination with low-dose calcium-based binding agents to achieve a greater reduction in serum phosphorus levels. Under current KDOQI guidelines, such combined therapy is recommended as the most suitable alternative for patients whose hyperphosphataemia is insufficiently controlled by monotherapy.
The prevalence of dyslipidaemias in patients with CKD is high and greater than in the general population [25] . CKD-related lipid disorders mainly consist of increased serum triglyceride levels, low HDL cholesterol levels and increased levels of small LDL lipoproteins and concentrations of lipoprotein (a). The lipid lowering effect of MCI-196 due to the inhibition of bile acid absorption should be of benefit in reducing the risk of cardiovascular disease. Animal studies have demonstrated MCI-196 to be ∼five times as potent as cholestyramine in reducing total cholesterol in rabbits [26] .
At present, it is unclear if the mechanism of this action results in amelioration in coronary artery calcification (CAC). Previous studies in patients with normal renal function have indicated an improvement in CAC in response to a reduction in serum LDL-cholesterol as a result of statin therapy [27] , but this relationship has not been studied extensively in CKD patients. The pathogenesis of atherosclerosis in dialysis patients would appear to be different from that in the general population and the benefit of using lipid-lowering drugs has not yet been demonstrated in CKD patients. The results of the 4D trial do not indicate a clear cardiovascular protective role of statins in type 2 diabetic patients on HD [28] , although the secondary endpoints of the study show a significant cardioprotection of statins with a relative risk reduction of 15%.
No serious adverse effects as a result of treatment with MCI-196 have been seen in this study. As MCI-196 is not absorbed, the most frequent adverse reactions seen were gastrointestinal disorders. This is similar to the level and type of adverse effects reported with the use of sevelamer [29] . Compliance is often an issue in this group of patients and it may have been expected to be an issue in this study with the significant number of pills taken daily. However, the results did not show this and conversely compliance was very good with between 86 and 93% compliancy in the three active dose groups. In future studies, it will be useful to evaluate the potential effects of MCI-196 on the status of lipophilic vitamins.
In summary, MCI-196 was effective in lowering serum phosphorus in HD patients without causing hypercalcaemia. In addition, there were significant reductions in the levels of Ca × P, uric acid and serum LDL cholesterol that may suggest a beneficial effect on cardiovascular disease risk. The results of further longer-term studies are required to confirm the efficacy and safety of 
